natgillin/translations-raw huggingface dataset:
The method of claim 1, wherein the pumping heterogeneous materials comprises pumping the heterogeneous materials in a conduit along a plane that is substantially parallel to the ground. 
Sustav iz patentnog zahtjeva 3, naznačen time, da je cjevovod prvog elektromagnetskog aplikatora postavljen horizontalno u odnosu na tlo.
Preferably, the calcium carbonate-containing rocks are comminuted to a particle size in the range of from 5 mm to 120 mm, preferably of from 10 to 100 mm, more preferably of from 20 to 80 mm, especially of from 35 to 70, e.g. 
Postupak prema bilo kojem od prethodnih zahtjeva, naznačen time da su stijene koje sadrže kalcijev karbonat usitnjene na veličinu čestica u rasponu od 5 mm do 120 mm, poželjno od 10 do 100 mm, još poželjnije od 20 do 80 mm, osobito od 35 do 70, npr.
Air cleaner in accordance with any one of the preceding claims, wherein a central holding element (9) supporting the at least one spiral filter rod (13) in a cantilevered fashion is rigidly connected only to the central part of said at least one spiral filter rod (13). 
Pročistač zraka u skladu s bilo kojim od prethodnih zahtjeva, naznačen time da je središnji element za držanje (9) koji podupire najmanje jednu spiralnu šipku (13) na konzolni način kruto spojen samo na središnji dio navedene najmanje jedne spiralne filtarske šipke (13).
Examples of di-substituted pyrazine derivatives that are particularly abundant in the present composition include fructosazines, particularly 2,5- and 2,6-substituted fructosazines. 
Primjeri di-supstituiranih derivata pirazina koji su naročito obilni u sadašnjem pripravku uključuju fruktozazine, naročito 2,5- i 2,6-supstituirane fruktozazine.
Nucleic acid according to item 1 or 2, wherein the nucleic acid does not contain a ribozyme, preferably a self-splicing ribozyme, and one of the group consisting of: a Neo gene, an inactivated promotor sequence, an inactivated enhancer sequence, a histon stem-loop processing signal, in particular a histon-stem loop processing sequence derived from mouse histon H2A614 gene. 
Nukleinska kiselina za uporabu prema zahtjevu 1 do 3, naznačena time da nukleinska kiselina ne sadrži ribozim, poželjno samostalno-spajajući ribozim, te jedan iz skupine koja sadrži: Neo gen, inaktiviranu sekvencu promotora, inaktiviranu sekvencu pojačivača, signal za procesiranje histona peteljka-omča, naročito sekvencu za procesiranje signala histona peteljka-omča dobivenu iz mišjeg histon gena H2A614.
two opposed second side members (5 and 6) are provided with third bending lines or score lines (16, 17 and 18, 19), characterized in that 
- < dva nasuprotna druga bočna dijela (5 i 6) imaju treće linije za savijanje ili razdjelne linije (16, 171 18, 19), naznačeno time što
As summarized in Table 4, when 2 beagle dogs were given a single oral dose of rapamycin at 10 mg/kg both dogs became lethargic and lost over 30% of their body weight in less than 1 week resulting from reduced food intake. 
Kako je prikazano u Tablici 4, kad je dvama beagle psima dana jedna oralna doza rapamicina od 10 mg/kg, oba psa postala su letargična i izgubila su preko 30% tjelesne težine u manje od tjedan dana, kao posljedica smanjenog unosa hrane.
HPLC = high performance liquid 
= tekućinska kromatografija visokog učinka conc.
Conservative amino acid substitutions of non-immunoglobulin protein comprising at least an Ig-like domain such as IL-18BP, IL6-IL6R, IL-6R and beta-galactosidase, may include synonymous amino acids within a group which have sufficiently similar physicochemical properties that substitution between members of the group will preserve the biological function of the molecule (Grantham, 1974) and/or provided that they have preserved at least one Ig-like domain. 
Konzervativne supstitucije aminokiselina za ne-imunoglobulinski protein koji posjeduje barem jednu domenu sličnu imunoglobulinskoj, poput IL-18BP, IL6-IL6R, IL-6R i beta-galaktozidaze, mogu uključivati sinonimne aminokiseline unutar skupine koje imaju dovoljno slična fizikalno-kemijska svojstva, tako da će zamjena jedne aminokiseline sa drugom unutar skupine očuvati biološku funkciju molekule (Grantham, 1974) i/ili da će očuvati barem jednu domenu sličnu imunoglobulinskoj.
A peptide consisting of an amino acid sequence selected from the group consisting of SEQ ID Nos: 23, 68, 69, and 70. 
Peptid koji se sastoji od sekvence aminokiselina u skladu s ID BR SEKV 58.
A method, according to claim 12, wherein the said image acquisition operation comprises a shot through one or more cameras (5) that film in a continuous cycle or in correspondence of the passing of the train. 
Postupak, prema zahtjevu 12, naznačen time da navedena radnja dobivanja slike obuhvaća slikanje kroz jednu ili više kamera (5) navedenog filma u neprekidnom ciklusu ili u skladu s prolaskom vlaka.
All of the hydrocarbon gaseous effluent that has three or fewer carbon atoms is sent, via the pipe (3 a), into a reaction section (H) in which it undergoes an oligomerization stage on a homogeneous metal catalyst or on a heterogeneous catalyst. 
Postupak prema jednom od patentnih zahtjeva 1 do 2, naznačen time što se cjelokupni navedeni plinoviti efluent koji ima tri ili više ugljikovih atoma dobivenih iz faze odvajanja šalje u reakcijski dio radi oligomerizacije koji sadrži homogeni metalni katalizator ili heterogeni katalizator.
no-reflow phenomenon following reperfusion; and 
fenomen odsutnosti protoka poslije reperfuzije; te
A compound, which is: or a pharmaceutically acceptable solvate or stereoisomer thereof. 
Spoj sukladno zahtjevu 1, s formulom: ili njegova farmaceutski prihvatljiva sol ili stereoizomer.
The pharmaceutical composition for use according to Claim 2, wherein the suppressor of collagen production by collagen-producing cells is selected from the group consisting of a TGFß inhibitor, HGF or a substance promoting the production thereof, a PPARY ligand, an angiotensin inhibitor, a PDGF inhibitor, relaxin or a substance promoting the production thereof, a substance that inhibits the production and secretion of an extracellular matrix component, a cell activity suppressor, a cell growth suppressor, and an apoptosis-inducing substance. 
Farmaceutski pripravak, namijenjen upotrebi u skladu s patentnim zahtjevom 2, naznačen time što se supresor proizvodnje kolagena u stanicama koje proizvode kolagen bira iz skupine koju čine inhibitor TGFB, HGF ili tvar koja potiče njegovu proizvodnju, PPARY ligand, angiotenzinski inhibitor, PDGF inhibitor, relaksin ili tvar koja potiče njegovu proizvodnju, tvar koja inhibira proizvodnju i izlučivanje komponente izvanstaničnog matriksa, supresor stanične aktivnosti, supresor staničnog rasta i tvar koja potiče apoptozu.
Pipeline pressure device according to one of the preceding claims, wherein the drive can be activated for adjustably varying the speed and thrust of the endless conveyor members. 
Cjevovodni tlačni uređaj, prema jednom od prethodnih zahtjeva, naznačen time da se pogon može aktivirati za prilagodno mijenjanje brzine i potiska A beskonačnih transportnih članova (5).
Display according to claim 1, characterized in that a discharge hood is installed between an evaporator (1) of an air conditioning device and the housing (7) of the display. 
Prikazivač prema zahtjevu 1, naznačen time, da je odvodni zaštitni pokrov postavljen između isparivača klimatizacijskog uređaja (1) i kućišta prikazivača (7). m> t>&
It is obvious that this sealing feature would also apply to embodiments one through five described above 
Očigledno je da se ova značajka brtvljenja odnosi također i na onih pet izvedbi koje su gore opisane.
is stable during storage at a temperature of 2-8°C up to at least 3 months (preferably at least 6 months, at least 9 months, at least 11 months, at least 1 year, 1.5 year or even 2 years or more), said stability as determined by OD320/OD280 measurement, SE-HPLC, IEX-HPLC, RP-HPLC, potency assay (such as Biacore or ELISA) and/or SDS-PAGE; 
manje od 10% polipeptida tvori piroglutamat na N-terminalnom kraju glutaminske kiseline tijekom skladištenja na temperaturi od 37+5*C do najmanje 2 tjedna (po mogućnosti najmanje 3 tjedna, najmanje 5 tjedana, najmanje 8 tjedana, najmanje 10 tjedana, najmanje 3 mjeseca, najmanje 6 mjeseci, najmanje 1 godinu, 1.5 godinu ili čak 2 godine ili više), te se % piroglutamata mjeri pomoću RP-HPLC;
It is preferred that the first binding domain specifically binding to human CD3 is arranged in the VH-VL orientation. 
(a) prvu vežuću domenu koja se specifično veže na ljudski CD3, i
Live cells were counted using a hemacytometer and Trypan blue exclusion, and the cell concentration was adjusted to 2×106 cells/ml. 
Žive stanice su prebrojane uporabom hemacitometra i Tryptan plavila, te je koncentracija stanica namještena na 2 x 10* stanica/ml.
each R8 and R9 are independently selected from hydrogen, CORa, COORa, substituted or unsubstituted C1-C12 alkyl, substituted or unsubstituted C2-C12 alkenyl, substituted or unsubstituted C2-C12 alkynyl, and substituted or unsubstituted C4-C12 alkenynyl; 
Ra se bira između vodika, COR,, COOR, supstituiranog ili nesupstituiranog C;-C,> alkila, supstituiranog ili nesupstituiranog C2-Cpx_ alkenila, supstituiranog ili nesupstituiranog C2-Ci2_ alkinila, 1 supstituiranog ili nesupstituiranog C4-C;2 alkeninila;
Method according to claim 7, wherein the solvent is methanol, ethanol, n-propanol, isopropanol, n-butanol, 2-methoxyethanol, isobutanol. 
Postupak u skladu s patentnim zahtjevom 7, naznačen time što je otapalo metanol, etanol, n-propanol, izopropanol, n-butanol, 2-metoksietanol, izobutanol.
wherein the tongue locking element at the first side of the tongue cooperates, in the coupled condition, with the groove locking element at the first lip, and wherein the second side of the tongue cooperates, in the coupled condition, with the second lip; 
Složeni element u skladu s bilo kojim od prethodnih patentnih zahtjeva, karakteriziran na način da je element zaključavanja (16) u žlijebu (14) smješten potpuno u materijalu odgovarajućeg vanjskog sloja (137).
applying an inverse primary transform to the primary transform coefficients to generate an output signal representing the respective channel in the respective audio block. 
(C) primjenu inverzne primarne transformacije na primarne transformacijske koeficijente da se dobije izlazni signal koji predstavlja odgovarajući kanal u odgovarajućem audio bloku.
The method according to claim 1, wherein the disease or disorder is ovarian cancer. 
Spoj ili farmaceutski sastav za uporabu prema zahtjevu 3, naznačen time, da bolest ili poremećaj je karcinom Jajnika.
Ar is a phenyl, pyridyl, imidazolyl, pyrimidinyl, pyridazinyl, or fused-bicyclic heteroaryl group unsubstituted or substituted with one, two, or three Rk substituents; 
Ar je fenil, piridil, imidazolil, pirimidinil, piridazinil, ili fuzionirana biciklična heteroaril grupa nesupstituirana ili supstituirana sa jednim, dva ili tri Rk supstituenta;
In certain embodiments, the invention relates to a method of preparing a cellulosic renewable identification number qualifying-fuel comprising, optionally, forming a renewable fuel oil via rapid thermal processing of a renewable cellulosic biomass feedstock; injecting greater than 90 wt. % of a petroleum fraction feedstock into a refinery process; injecting less than 10 wt. % of the renewable fuel oil into the refinery process proximate the injection point of the petroleum fraction feedstock; and co-processing the petroleum fraction feedstock and renewable fuel oil to produce the cellulosic-renewable identification number qualifying-fuel; wherein the renewable fuel oil has a pH of 1.5-6, a solids content of less than 2.5 wt. %, and a water content of 20-45 wt. %. In certain embodiments, the invention relates to a method of preparing a fuel derived at least in part from a renewable fuel processed through a refinery conversion unit, for example an FCC. 
Postupak proizvodnje goriva, koji sadrži: ko-procesiranje sirovine u prisutnosti katalizatora, gorivo sadrži proizvod fluidiziranog katalitičkog krekera koji ko-procesira sirovinu, navedena sirovina sadrži: i) 80-99,95 wt. % sirovine frakcije petroleja; i 11)0,05-7 wt. % sirovine neobogaćenog obnovljivog ulja goriva, neobogaćeno obnovljivo ulje goriva nastaje mehaničkim mljevenjem celulozne biomase nakon čega slijedi brzo termalno procesiranje, isključivo od hidrodeoksigenacije, hidrotretiranja ili katalitičkog procesiranja, naznačen time što neobogaćeno obnovljivo ulje goriva ima a) u rasponu od između 35-80 wt. % sadržaja ugljika na bazi bez vlage; b) te u rasponu od između 20-50 wt. % sadržaja kisika na bazi bez vlage; te c) sadržaj vode u rasponu od između 10-40 wt. %. Postupak prema zahtjevu 1, naznačen time što je proizvedeno gorivo transportacijsko gorivo.
The effects of 1-[3-[3-(4-chlorophenyl)propoxy]propyl]-piperidine monohydrochloride on sleep-wake cycle control have been investigated in freely moving cats and mice. 
Učinci 1-[3-[3-(4-klorfenil)propoksi]propil]-piperidin monoklorida na kontrolu ciklusa spavanja i budnosti su istraživani kod slobodno pokretljivih mačaka i miševa.
a container that contains a pharmaceutical composition containing a peptide according to any one of claims 1 to 4, the nucleic acid or the expression vector according to claim 5, a cell according to claim 7 or 8, or an activated cytotoxic T lymphocyte according to claim 11, in solution or in lyophilized form; and 
posudu koja sadrži farmaceutski sastav koji sadrži peptid u skladu s bilo kojim od patentnih zahtjeva od 1 do 4, stanicu u skladu s patentnim zahtjevom 7 ili aktivirani citotoksični T limfocit u skladu s patentnim zahtjevom 10, u otopini ili u liofiliziranom obliku;
The oral formulations also comprise protracted-release forms, such as enteric-coated tablets or granules. The solid oral compositions can be prepared with conventional mixing, filling or compression methods. 
Oralne formulacije također sadrže oblike s produljenim oslobađanjem kao što su prevučene tablete otporne na želučanu tekućinu sok ili granule, čvrsti oralni pripravci se mogu pripraviti uobičajenim metodama miješanja, punjenja i kompresije.
During processing of the cement according to the invention, or of a binder comprising the same, a water/binder value of 0.2 to 2 is suitable, preferably of 0.3 to 0.8, and still more preferably of 0.45 to 0.72. 
Uporaba vezivnog sredstva sukladno bilo kojem od zahtjeva 1 do 7, ili pribavljivo sukladno bilo kojem od zahtjeva 8 do 11, u kombinaciji s agregatom za proizvodnju betona, morta ili žbuke, pri čemu je vrijednost vode/veziva prilagođena 0.2 do 2 prilagođena.
The IL-17 binding antibody or active fragment thereof according to claim 1, wherein said VL comprises in sequence hypervariable regions CDR1', CDR2' and CDR3', said CDR1' having the amino acid sequence SEQ ID NO:4, said CDR2' having the amino acid sequence SEQ ID NO:5, and said CDR3' having the amino acid sequence SEQ ID NO:6 or direct CDR' equivalents thereof. 
VH koji obuhvaća u nizu hipervarijabilna područja CDR1, CDR2 i CDR3, gdje navedeno područje CDR1 ima aminokiselinsku sekvencu SEQ ID NO:1, navedeno područje CDR2 ima aminokiselinsku sekvencu SEQ ID NO:2, i navedeno područje CDR3 ima aminokiselinsku sekvencu SEQ ID NO:3, dok su hipervarijabilna područja određena prema Kabat-definiciji; ili
phase transformation 
Početak fazne transformacije uz
Sixty minutes after product administration, a paper patch saturated with FeCl3 solution (70%) was placed (and not removed for the whole duration of the experiment) on the left carotid artery downstream from the sounding of flow to initiate thrombosis. 
60 minuta nakon izdanog proizvoda, stavljen je papirnati flaster zasićen s FeCl; otopinom (70%) (1 nije uklonjen za sve vrijeme trajanja pokusa) na lijevu karotidnu arteriju silazno od ozvučenja protoka da izazove trombozu.
wherein (i) and (ii) are covalently linked by intervening nucleotides, wherein the single molecule DNA-targeting RNA is capable of forming a complex with the Cas9 protein and hybridization of the targeter-RNA to the target sequence is capable of targeting the Cas9 protein to the target DNA; and 
RNK jednostruke molekule koja cilja na DNK, ili DNK-polinukleotid koji kodira navedenu RNK koja cilja na DNK, naznačen/a time, da obuhvaća sljedeće: segment koji cilja na DNK, te koji obuhvaća nukleotidnu sekvencu koja je komplementarna ciljanoj sekvenci u ciljanoj DNK; i
Apparatus according to claim 1, wherein the receiving means is covered with a material comprising membranes, geo-membranes, geotextile membranes, plastic liners, concrete, or coated concrete, or a combination thereof. 
Uređaj iz patentnog zahtjeva 1, pri čemu je sredstvo prihvaćanja prekriveno materijalom koji obuhvaća membrane, geomembrane, geotekstilne membrane, plastične podloške, beton, obloženi beton, ili njihove kombinacije.
a template comprising a cap serving as a support substantially in said first plane, and three peripheral shoes for folding wire legs by pressing for folding the three wires at a certain distance from said an overlap region for twisting, in a plane substantially perpendicular to said first plane; means for connecting a rim formed by a third wire by simultaneous passage of the third wire through the three second loops of a cage formed from the first and second wires for cooperating with the rim by translation in a direction substantially perpendicular to said first plane, and means for closing the three second loops by pressing their second free ends in a direction parallel to said first plane. 
- kalup u obliku kape koja služi kao nosač uglavnom u navedenoj prvoj ravnini, te tri periferne cipele na svakom kraku, namijenjene savijanju navedenih krakova pritiskanjem radi savijanja tri žice na određenoj udaljenosti od navedenog uvinuća, u ravnini koja je uglavnom okomita u odnosu na navedenu prvu ravninu; gdje stroj dodatno ima: - sredstvo za povezivanje obruča istodobnim prolaskom kroz tri druge omče (6) navedenog kaveza prijelazom u smjeru uglavnom okomitom u odnosu na navedenu prvu ravninu kaveza, i - sredstvo za zatvaranje tri druge omče pritiskanjem njihovih drugih slobodnih krajeva u smjeru paralelnom u odnosu na navedenu prvu ravninu.
The process of claim 16, wherein from 10 to 1000 ppm by weight of ferric chloride is maintained in the reaction zone of step (iii) or from 10 to 20000 ppm by weight of ferric chloride is maintained in the reaction zone of step (iv). 
Postupak prema zahtjevu 16, gdje se od 10 do 1090 ppm po težini željezovog(III) klorida održava u reakcijskoj zoni u koraku (iii) ili se od 10 do 20000 ppm po težini željezovog(III) klorida održava u reakcijskoj zoni u koraku (iv).
A process for the preparation of 7-ethyl-10-hydroxycamptathecin of formula I comprising oxidizing 7-ethyl-1,2,6,7-tetrahydrocamptothecin of formula IV with an oxidizing agent selected from the group comprising iodosobenzene, an ester of iodosobenzene, sodium periodate, potassium periodate, potassium peroxodisulfate and ammonium peroxodisulfate, in a solvent formed by a saturated aliphatic monocarboxylic acid containing 1 to 3 carbon atoms, and in the presence of water, wherein the water is used in an amount of 0.98 to 1.88 mol per 1 mol of 7-ethyl-1,2,6,7-tetrahydrocamptothecin. 
(IV) se oksidira jodobenzen-diacetatom u octenoj kiselini, prisutnosti vode, u uvjetima koji se sastoje u tom da se jodobenzendiacetat upotrebljava u količini od 0,99 do 1,85 mol na 1 mol 7-etil-1,2,6,7-tetrahidrokamptotecina, octenu kiselinu se upotrebljava u količini od 668 do 1001 mol na 1 mol 7-etil-1,2,6,7-tetrahidrokamptotecina, vodu se upotrebljava u količini od 980 do 1880 mol na 1 mol 7-etil-1,2,6,7-tetrahidrokamptotecina, a oksidaciju se provodi na temperaturi od 15 do 30 "C, u trajanju od 5 do 30 minuta.
Said insoluble, non selective, non digestible polysaccharide is preferably selected from the group consisting of cellulose, hemicellulose, cereal fibres, wheat fibres, oat fibres, apple fibres, orange fibres, tomato fibres or can be a combination thereof. 
Rečeni netopljivi, neselektivni, neprobavljivi polisaharid se, po mogućnosti, bira iz skupine koju čine celuloza, hemiceluloza, vlakna žitarica, zobena vlakna, jabučna vlakna, narančina vlakna, ili to mogu biti njihove kombinacije.
A process according to claim 7, wherein the step (f) comprises crystallisation using a toluene and isohexane solvent system. 
Postupak prema zahtjevu 7, naznačen time da korak (f) sadrži kristalizaciju uz korištenje sustava otapala toluena i izoheksana.
Method according to claim 24 or 25, characterized in that vibration reduction means (56) of an active type are provided by which vibration movements in the hoisting wire system (22) are actively compensated. 
Postupak sukladno zahtjevu 22 ili 23, naznačen time što su sredstva za smanjenje vibracije (56) aktivnog tipa pružena pokretom vibracije kod sustava žica za podizanje (22) aktivno kompenzirana.
In one embodiment, a compound of formula (IB) or a salt thereof is provided, wherein R1, p, R3 and R4 are as defined for formula (I): 
Spoj, ili njegova farmaceutski prihvatljiva sol, koji odgovara spoju formule (IB), naznačen time što Ri, p, Rz i Ry su definirani u skladu s patentnim zahtjevom 1.
is free of phosphate buffering agents; and 
i nema sredstva za puferiranje fosfata.
or a pharmaceutically acceptable salt thereof. A method of treating alopecia in a mammal, comprising topically administering to the mammal a pharmaceutical composition comprising a therapeutically effective amount of a compound, or a pharmaceutically acceptable salt thereof, having the structure of Formula I: 
Farmaceutski pripravak naznačen time da sadrži terapeutski učinkovitu količinu spoja prema zahtjevu 1 ili njegovu farmaceutski prihvatljivu sol koji ima strukturu s Formulom I: pri čemu R' je supstituiran ili nesupstituiran heteroaril, pri čemu je heteroaril odabran iz skupine koju čine
A compound of general formula I: wherein: 
Spoj opće formule (I):
a total amount of protein of at least 60% (w/w) on a dry weight basis relative to the total weight of the denatured whey protein composition, 
– ukupnu količinu čvrstih tvari u pripravku denaturiranog proteina sirutke od najmanje 2 % (tež./tež.) u odnosu na ukupnu težinu napitka, gdje pripravak denaturiranog proteina sirutke sadrži:
a cumulative total amount of leucine per unit volume greater than approximately 5.5 mM; 
(iii) kumulativna ukupna količina leucina po jedinici volumena veća od približno 5,5 mM;
the antibody that is selected from anti-PD-1 antibodies, anti-PD-L1 antibodies and anti-PD-L2 antibodies is for being administered first followed by administration of the anti-KIR antibody; or 
anti-PD-1 antitijelo je za administraciju prvo praćeno administracijom anti-KIR antitijela; ili
A kit comprising: a container that contains a pharmaceutical composition containing a peptide according to any one of claims 1 to 4, the nucleic acid or the expression vector according to claim 5, a cell according to claim 7, or an activated cytotoxic T lymphocyte according to claim 10, in solution or in lyophilized form; 
posudu koja sadrži farmaceutski sastav koji sadrži peptid u skladu s bilo kojim od patentnih zahtjeva od 1 do 3, nukleinskom kiselinom ili vektorom ekspresije u skladu s patentnim zahtjevom 4, stanicom u skladu s patentnim zahtjevom 6 ili 7 ili aktiviranim citotoksičnim T limfocitom u skladu s patentnim zahtjevom 10, u otopini ili u liofiliziranom obliku; te
The wall element will generally be plane, but it may also be curved around one or more axes. 
Zidni element uobičajeno će biti ravan, ali može biti i zakrivljen oko jedne ili više osi.
The compounds of the present invention can be readily prepared according to this novel process utilizing a variety of starting materials that are commercially available or readily prepared by synthetic regimes which would be familiar to one skilled in the art. 
Spojevi prikazanog izuma se mogu redovno pripremiti prema tim novim postupcima korištenjem različitih polaznih materijala koji su komercijalno dostupni ili svježe pripremljeni režimima sinteze što je blisko stručnjacima iz struke.
The method according to claim 1, wherein the solubilisation enhancer is an acid. 
Postupak sukladno patentnom zahtjevu 1, naznačen time da je pojačivač otapanja kiselina.